FibroGen (NASDAQ:FGEN) Raised to Hold at Wall Street Zen

Key Points

• FibroGen was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating, indicating a more favorable outlook from analysts.
• HC Wainwright maintains a "buy" rating with a price target of $43.00 for FibroGen shares, reflecting analyst confidence in the company's prospects.
• FibroGen reported a loss of $3.38 per share in its latest earnings report, falling short of the analyst consensus estimate of a loss of $2.25 per share.

Wall Street Zen upgraded shares of FibroGen (NASDAQ:FGEN - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and set a $43.00 target price on shares of FibroGen in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.00.

FibroGen Price Performance

Shares of FGEN stock traded down $0.19 during mid-day trading on Friday, hitting $11.84. The company had a trading volume of 15,459 shares, compared to its average volume of 51,370. The company has a market capitalization of $47.83 million, a P/E ratio of -31.16 and a beta of 0.76. The stock's 50 day moving average price is $9.21 and its 200-day moving average price is $8.18. FibroGen has a 52-week low of $4.50 and a 52-week high of $21.94.

FibroGen (NASDAQ:FGEN - Get Free Report) last announced its earnings results on Monday, August 11th. The biopharmaceutical company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.25) by ($1.13). The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.88 million. On average, equities research analysts expect that FibroGen will post -0.8 earnings per share for the current year.

Insider Activity at FibroGen

In related news, Director James A. Schoeneck purchased 23,567 shares of FibroGen stock in a transaction dated Monday, June 30th. The shares were acquired at an average price of $5.07 per share, for a total transaction of $119,484.69. Following the acquisition, the director directly owned 39,666 shares in the company, valued at approximately $201,106.62. The trade was a 146.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.98% of the stock is currently owned by corporate insiders.

Institutional Trading of FibroGen

Several institutional investors and hedge funds have recently bought and sold shares of FGEN. Velan Capital Investment Management LP acquired a new position in FibroGen in the 4th quarter valued at about $42,000. Connective Capital Management LLC acquired a new position in FibroGen in the 2nd quarter valued at about $80,000. HighTower Advisors LLC grew its position in FibroGen by 292.8% in the 1st quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company's stock valued at $125,000 after acquiring an additional 301,500 shares in the last quarter. Squarepoint Ops LLC acquired a new position in FibroGen in the 4th quarter valued at about $205,000. Finally, Mackenzie Financial Corp grew its position in FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company's stock valued at $290,000 after acquiring an additional 441,083 shares in the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.